NCT00406562View on ClinicalTrials.gov

Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.

PHASE3CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

January 31, 2007

Study Completion Date

February 28, 2007

Conditions

TetanusDiphtheriaAcellular Pertussis

Interventions

BIOLOGICAL

Boostrix

Trial Locations (1)

Unknown

GSK Investigational Site, Suining

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00406562 - Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age. | Biotech Hunter | Biotech Hunter